School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Hemab Therapeutics Holdings, Inc. COAG

Healthcare · Biotechnology

$31.62last close 2026-10-09 · market cap $1.48B · delayed data

Trailing returns

1M-28.94%
3M-15.00%

Basis: Adjusted daily closes.

What it does

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.

Open COAG in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies